Author

A. Nelde

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:dimensionality reduction· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Marcu· 2 shared H. Schuster· 2 shared H.-G. Rammensee· 2 shared M. Ghosh· 2 shared S. Stevanovic· 2 shared A. Dulovic· 1 shared A. Scholz· 1 shared A. Zeck· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Marcu

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response

T. R. Wagner, P. D. Kaiser, M. Gramlich, E. Ostertag, N. Ruetalo, D. Junker, J. Haering, B. Traenkle, M. Becker, A. Dulovic, H. Schweizer, S. Nueske, A. Scholz, A. Zeck, K. Schenke-Layland, , U. Rothbauer

The paper develops NeutrobodyPlex, a multiplex assay using bivalent nanobodies to analyze neutralizing antibodies against SARS-CoV-2 in patient sera.

bioRxiv · Sep 22, 2020 · PreprintImmunology

An innovative approach for HLA typing, molecular tumor testing and the validation of tumor exclusive antigens

M. Ghosh, L. Bichmann, J. Scheid, G. Gueler, H. Schuster, M. Di Marco, A. Marcu, M. Beyer, A. Nelde, L. K. Freudenmann, L. Muehlenbruch, M. W. Loeffler, O. Kohlbacher, H.-G. Rammensee, S. Stevanovic

The paper describes an innovative approach for HLA typing, molecular tumor testing, and validation of tumor-exclusive antigens but has been withdrawn by the authors.

bioRxiv · Jun 5, 2020 · PreprintImmunology

Validation of a high-performance liquid chromatography-tandem mass spectrometry immunopeptidomics assay for the identification of HLA class I ligands suitable for pharmaceutical therapies

M. Ghosh, M. Gauger, A. Marcu, A. Nelde, M. Denk, H. Schuster, H.-G. Rammensee, S. Stevanovic

The paper validates an LC-MS/MS immunopeptidomics assay for identifying HLA class I ligands suitable for personalized immunotherapy.

bioRxiv · Oct 29, 2019Immunology